Cytometric analysis of cell suspension generated by cavitron ultrasonic surgical aspirator in pediatric brain tumors
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
Grantová podpora
15-26588A
Ministerstvo Zdravotnictví Ceské Republiky
UNCE 204012
Univerzita Karlova v Praze
LO1604
Ministerstvo Školství, Mládeže a Tělovýchovy
PubMed
30827009
DOI
10.1007/s11060-019-03135-w
PII: 10.1007/s11060-019-03135-w
Knihovny.cz E-zdroje
- Klíčová slova
- Cavitron ultrasonic surgical aspirator (CUSA), Flow cytometry, Mass cytometry, Pediatric brain tumors,
- MeSH
- analýza jednotlivých buněk MeSH
- cisplatina metabolismus MeSH
- leukocyty metabolismus patologie MeSH
- lidé MeSH
- nádorové biomarkery metabolismus MeSH
- nádory mozku diagnóza metabolismus patologie chirurgie MeSH
- neurochirurgické výkony přístrojové vybavení MeSH
- průtoková cytometrie MeSH
- ultrazvuková terapie přístrojové vybavení MeSH
- viabilita buněk MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- cisplatina MeSH
- nádorové biomarkery MeSH
PURPOSE: The aim of this study was to test the possibility of using specimens obtained by a cavitron ultrasonic surgical aspirator (CUSA) in flow and mass cytometry investigations of pediatric brain tumors. METHODS: CUSA specimens obtained from 19 pediatric patients with brain tumors were investigated. Flow and mass cytometry methods were applied to analyze the composition of material collected using the CUSA. Cell suspensions were prepared from CUSA aspirates. Then sample viability was assessed by conventional flow cytometry and subsequently stained with a panel of 31 metal-labeled antibodies. RESULTS: Viability assessment was performed using conventional flow cytometry. Viability of cells in the acquired samples was below 50% in 16 of 19 cases. A mass cytometry investigation and subsequent analysis enabled us to discriminate brain tumor cells from contaminating leukocytes, whose proportions varied across the specimens. The addition of the viability marker cisplatin directly into the mass cytometry panel gave the means to selecting viable cells only for subsequent analyses. The proportion of non-viable cells was higher among tumor cells compared leukocytes. CONCLUSIONS: When the analysis of the tumor cell immunophenotype is performed with markers for determining viability, the expression of the investigated markers can be evaluated. Suitable markers can be selected by high-throughput methods, such as mass cytometry, and those that are diagnostically relevant can be investigated using flow cytometry, which is more flexible in terms of time.
Zobrazit více v PubMed
Mol Cancer. 2006 Dec 02;5:67 PubMed
Anal Chem. 2009 Aug 15;81(16):6813-22 PubMed
Leuk Res. 2011 Aug;35(8):1111-3 PubMed
Trends Immunol. 2012 Jul;33(7):323-32 PubMed
Exp Cell Res. 2013 Feb 15;319(4):517-28 PubMed
Nat Biotechnol. 2013 Jun;31(6):545-52 PubMed
Nat Neurosci. 2013 Oct;16(10):1373-82 PubMed
Cancers (Basel). 2013 Apr 03;5(2):357-71 PubMed
Cytometry B Clin Cytom. 2014 Jul;86(4):288-91 PubMed
Int J Oncol. 2015 Jul;47(1):91-6 PubMed
Oncotarget. 2015 Nov 17;6(36):38881-900 PubMed
Acta Neuropathol. 2016 Jun;131(6):803-20 PubMed
CNS Oncol. 2016 Jul;5(3):159-73 PubMed
J Neurooncol. 2017 Jan;131(2):233-244 PubMed
N Engl J Med. 2016 Dec 29;375(26):2561-9 PubMed
J Neurooncol. 2017 Sep;134(3):505-512 PubMed
Sci Transl Med. 2017 Mar 15;9(381): PubMed
Biophys Rev. 2016 Mar;8(1):5-9 PubMed
Oncoimmunology. 2017 Nov 6;7(2):e1391973 PubMed
Brain Tumor Pathol. 2018 Apr;35(2):81-89 PubMed
J Cancer Res Clin Oncol. 2018 Jul;144(7):1227-1237 PubMed
Cancer Res. 2018 Aug 15;78(16):4745-4759 PubMed
Clin Cancer Res. 2019 Apr 1;25(7):2042-2048 PubMed
World Neurosurg. 2018 Dec 26;:null PubMed
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):997-1006 PubMed
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574 PubMed
Cytometry A. 2019 Mar;95(3):290-301 PubMed
Oncogene. 2019 Feb 11;:null PubMed
Clin Neurosurg. 1983;31:497-505 PubMed
